This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified July 2011 by Hadassah Medical Organization
Information provided by:
Hadassah Medical Organization Identifier:
First received: July 3, 2011
Last updated: July 5, 2011
Last verified: July 2011
The genetic factors associated with variability in CYP2C9 induction have not been elucidated. The hypothesis underlying this study is that following 7 days treatment with rifampicin, a known CYP450 inducer, the genetic variability in regulatory elements controlling CYP2C9 expression will be associated with the magnitude of change in INR response to warfarin and in CYP2C9-mediated warfarin metabolism.

Condition Intervention
Healthy Subjects Drug: Rifampicin

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • International Normalized Ratio (INR) [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Warfarin concentration [ Time Frame: 6 weeks ]

Estimated Enrollment: 150
Study Start Date: July 2011
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rifampicin
Consecutive treatments with rifampicin and placebo
Drug: Rifampicin
oral, 450 mg/day , 7 days


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects

Exclusion Criteria:

  • Consumption of any medication during 30 days
  • Smoking
  • Alcohol consumption
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01388075

Contact: Mordechai Muszkat, MD 972-6777111 ext 73793

Hadassah Hebrew University Medical Center Not yet recruiting
Jerusalem, Israel, 91120
Contact: Mordechai Muszkat, MD    972-2-6777111 ext 73793   
Principal Investigator: Mordechai Muszkat, MD         
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

Responsible Party: Mordechai Muszkat, MD, Hadassah Medical Organization Identifier: NCT01388075     History of Changes
Other Study ID Numbers: HMO-0451-10
Study First Received: July 3, 2011
Last Updated: July 5, 2011

Keywords provided by Hadassah Medical Organization:
Genetic variability

Additional relevant MeSH terms:
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers processed this record on August 17, 2017